Abstract
Antibody-drug conjugates have transformed treatment for urothelial cancer (UC). Enfortumab vedotin is the new standard of care in the first-line setting for advanced UC. A personalised approach targeting HER2 in UC is currently being explored.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have